Aalto Bio Reagents, Dublin, Ireland, has released its new recombinant SARS-CoV-2 nucleocapsid protein (code CK 6404) for diagnostic test manufacturers, vaccine developers, and researchers globally.


Philip Noone, Aalto Bio Reagents.

“Patients are currently being screened for the virus by PCR,” says Philip Noone, chief executive officer of Aalto Bio Reagents. “However, there is an important need for serological tests as well to detect all those mild or even asymptomatic cases that may otherwise be missed. Sero-epidemiologic investigations, such as those aimed to better understand transmission characteristics and severity of covid-19, are also essential.

“The medical field and diagnostic industry has an unrelenting requirement for access to the most scientifically proven raw materials in outbreak situations like this, where fast diagnosis is required,” adds Noone. “With our new SARS-CoV-2 nucleocapsid protein we endeavour to meet this urgent demand.”

For more information, visit Aalto Bio Reagents.